Dublin, Sept. 19, 2024 (GLOBE NEWSWIRE) -- The "Crohn's Disease - Pipeline Insight, 2024" clinical trials has been added to ResearchAndMarkets.com's offering.
This "Crohn's Disease - Pipeline Insight, 2024" report provides comprehensive insights about 70+ companies and 80+ pipeline drugs in Crohn's Disease pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
The report outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Crohn's Disease pipeline landscape is provided which includes the disease overview and Crohn's Disease treatment guidelines. The assessment part of the report embraces, in depth Crohn's Disease commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Crohn's Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Crohn's Disease R&D. The therapies under development are focused on novel approaches to treat/improve Crohn's Disease.
Crohn's Disease Emerging Drugs Chapters
This segment of the Crohn's Disease report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Crohn's Disease Emerging Drugs
Ozanimod: Bristol-Myers Squibb
Ozanimod (Zeposia) is an oral, sphingosine 1-phosphate (S1P) receptor modulator that binds with high affinity to S1P receptors 1 and 5. Zeposia reduces the capacity of lymphocytes to migrate from lymphoid tissue, reducing the number of circulating lymphocytes in peripheral blood. The company is currently investigating the drug for the treatment of moderately to severely active Crohn's disease in the ongoing Phase III YELLOWSTONE clinical trial program.
Etrasimod: Pfizer
Etrasimod is an investigational oral drug being studied for the treatment of Crohn's disease. It is a selective sphingosine 1-phosphate receptor modulator designed to treat immune-mediated inflammatory disorders. Clinical trials, such as the CULTIVATE trial, are evaluating the efficacy, safety, and tolerability of etrasimod in subjects with moderately to severely active Crohn's disease. Etrasimod has shown promising results in inducing and maintaining remission in patients with Crohn's disease, demonstrating significant improvements compared to a placebo in clinical trials. Currently, the drug is in the Phase III stage of its development for the treatment of Crohn's Disease.
CBP-307: Suzhou Connect Biopharmaceuticals
CBP-307 is an orally available, next generation small molecule modulator of the sphingosine-1-phosphate 1 receptor (S1P1), a G-protein coupled receptor (GPCR) that plays a central role in regulating T cell movement and is a validated therapeutic target. S1P1 mediates the transit of T cells from lymph nodes into circulation and, as a result, the migration of T cells to tissues to release inflammatory mediators.6-10 CBP-307 causes T cells to internalize S1P1, trapping T cells inside the lymph nodes and preventing them from migrating to sites of inflammation.CBP-307 has high potency and selectivity11 and is designed to be the most potent modulator of the S1P1 drug class, if approved. CBP-307 has no significant activity for S1P3, a receptor subtype with known safety concerns, and significantly lower potency for S1P4 and S1P5 than S1P1. Currently, the drug is in the Phase II stage of its development for the treatment of Crohn's Disease.
IMU-856: Immunic
IMU-856 is an orally available and systemically acting small molecule modulator that targets SIRT6 (Sirtuin 6), a protein which serves as a transcriptional regulator of intestinal barrier function and regeneration of bowel epithelium. Based on preclinical data, the compound appears to represent a new and potentially disruptive approach for the treatment of intestinal diseases by potentially restoring the intestinal barrier function while maintaining immunocompetency. Currently, the drug is in the Phase I stage of its development for the treatment of Crohn's Disease.
Crohn's Disease: Therapeutic Assessment
Major Players in Crohn's Disease
There are approx. 70+ key companies which are developing the therapies for Crohn's Disease. The companies which have their Crohn's Disease drug candidates in the most advanced stage, i.e. phase III include, Bristol-Myers Squibb.
Crohn's Disease: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Crohn's Disease therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Crohn's Disease drugs.
Key Questions
- How many companies are developing Crohn's Disease drugs?
- How many Crohn's Disease drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Crohn's Disease?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Crohn's Disease therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Crohn's Disease and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Anssen
- RedHill Biopharma
- Amgen
- Pfizer
- Prometheus Biosciences
- AgomAb Therapeutics
- Hoffmann-La Roche
- Gilead Sciences
- Eli Lilly and Company
- Celgene
- AstraZeneca
- Mesoblast
- Alfasigma
- Tiziana Life Sciences
- Abivax
- Arena Pharmaceuticals
- Cytocom, HAV Vaccines Ltd
- Enzo Biochem Inc.
- Stero Biotechs
- Reistone Biopharma Company Limited
- Qu Biologics
- Pfizer
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharmaceuticals
- Soligenix
- Immunic
- Pfizer
- Atlantic Healthcare
- 4D Pharma
- Landos Biopharma
- Janssen
- Roche
- Eisai
- Bristol-Myers Squibb
Key Products
- Guselkumab
- ABP-654
- RHB-104
- Etrolizumab
- PRA-023
- AGMB-129
- Filgotinib
- Mirikizumab
- Ozanimod
- Brazikumab
- Remestemcel-L
- Rifaximin
- Foralumab
- ABX-464
- Etrasimod
- CYTO-201
- Masitinib
- HAV anti-MAP vaccine
- Alequel
- Cannabidiol
- SHR0302
- QBECO-SSI
- PRV-6527
- PF-06651600
- MT-1303
- TAK-018
- SGX203
- IMU 838
- Alicaforsen
- Bacteroides thetaiotaomicron
- BT-11
- JNJ-64304500
- E6011
Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
Route of Administration
- Oral
- Intravenous
- Subcutaneous
- Parenteral
- Topical
- Molecule Type
Products have been categorized under various Molecule types such as
- Recombinant fusion proteins
- Small molecule
- Monoclonal antibody
- Peptide
- Polymer
- Gene therapy
- Product Type
Crohn's Disease Report Insights
- Crohn's Disease Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
Crohn's Disease Report Assessment
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/s8fr2i
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
